
Mara Serena Serafini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2008713/publications.pdf Version: 2024-02-01



#	Article	IF	CITATION
1	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1057.	1.7	25
2	Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures. Cancers of the Head & Neck, 2020, 5, 2.	6.2	22
3	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide <scp>EU</scp> Project. Head and Neck, 2021, 43, 601-612.	0.9	18
4	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. Cells, 2020, 9, 1828.	1.8	13
5	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. Oral Oncology, 2019, 90, 94-101.	0.8	12
6	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 922.	1.7	12
7	Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus–Positive Oropharyngeal Carcinoma. JCO Precision Oncology, 2021, 5, 1666-1676.	1.5	6
8	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. BMC Cancer, 2021, 21, 561.	1.1	5
9	Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. Frontiers in Oncology, 2021, 11, 799453.	1.3	5
10	Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. Oral Oncology, 2022, 126, 105756.	0.8	1
11	Co-existance of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial Journal of Clinical Oncology, 2017, 35,	0.8	0